Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Treating Early and Intermediate HCC: Surgery and Localized Options

At a Glance

Early and intermediate hepatocellular carcinoma (HCC) can often be treated with curative or localized therapies. Options include surgical resection, liver transplantation, thermal ablation, TACE, and TARE. Treatment choice depends on tumor size, tumor quantity, and overall liver health.

Return to Home

If your cancer is in the Early (BCLC 0/A) or Intermediate (BCLC B) stage, you likely have several treatment options. In these stages, the goal is often curative—meaning doctors aim to remove or destroy the tumor entirely—or at least to control the disease for a long period [1][2].

Curative-Intent Options (Early Stage)

For patients with a small, localized tumor and a relatively healthy liver, there are three main paths to a cure:

  • Surgical Resection (Liver Surgery): A surgeon removes the tumor and a small “margin” of healthy tissue around it [3]. This is often a first-line choice if the rest of your liver is working well and you do not have portal hypertension (high blood pressure in the liver’s veins) [3][4].
  • Liver Transplantation: This is often considered the “ultimate” cure because it removes the tumor and the diseased liver that caused it [1][5]. It is the preferred choice if your liver function is poor or if you have multiple small tumors [1][6]. To qualify, patients typically must fall within the Milan Criteria (one tumor ≤\le 5 cm or up to three ≤\le 3 cm) [5][7].
  • Thermal Ablation: Instead of surgery, doctors use a needle-like probe to “cook” the tumor with heat—either Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) [8][9]. This is less invasive than surgery and is highly effective for very small tumors (less than 3 cm) [10][11].

Locoregional Therapies (Intermediate Stage)

When there are more tumors, or if they are larger, doctors use “localized” treatments that go through the blood vessels directly to the liver.

  • TACE (Transarterial Chemoembolization): A doctor threads a catheter to the liver and delivers a high dose of chemotherapy directly into the tumor’s blood supply, then “plugs” the vessel to starve the tumor [12][13]. This is a standard for intermediate-stage HCC [2].
  • TARE (Transarterial Radioembolization / Y-90): This is similar to TACE, but instead of chemotherapy, it uses tiny radioactive beads to deliver internal radiation directly to the tumor [12][13]. It may have fewer immediate side effects, like the “post-embolization syndrome” (fever and pain) often seen with TACE [14][15].

The Bridge and the Ladder: Moving Toward Transplant

Sometimes these treatments are used not just to control the cancer, but to help a patient qualify for a liver transplant.

  1. Bridging Therapy: If you already qualify for a transplant but have to wait for an organ, doctors use TACE, TARE, or ablation as a “bridge” to keep the tumor from growing while you wait [16][17].
  2. Downstaging: If your tumors are currently too big or too numerous for a transplant, doctors may use these same therapies to shrink the cancer into the acceptable Milan Criteria [17][18]. If the tumors shrink and stay stable, research shows that your survival after a transplant can be just as good as someone who qualified from the start [18][19].
Treatment How it Works Goal
Resection Physically removing the tumor [3]. Cure [3].
Transplant Replacing the whole liver [1]. Total Cure (Tumor + Liver) [6].
Ablation Burning the tumor with heat [8]. Destroy small tumors [10].
TACE / TARE Starving the tumor via blood vessels [12]. Shrink tumors or “bridge” to transplant [17].

Your team will look at your ALBI grade and Child-Pugh score to decide which of these paths is safest for you, ensuring your treatment doesn’t overwhelm your liver’s remaining strength [20][21].

Common questions in this guide

What are the Milan criteria for a liver transplant?
The Milan criteria are medical guidelines used to determine if a patient with HCC qualifies for a liver transplant. To qualify, a patient typically must have a single tumor that is 5 centimeters or smaller, or up to three tumors that are each 3 centimeters or smaller.
What is the difference between TACE and TARE?
Both are localized treatments delivered directly to the liver's blood vessels, but they use different methods to destroy the tumor. TACE delivers a high dose of chemotherapy to the tumor, while TARE uses tiny radioactive beads to deliver internal radiation.
What does bridging therapy mean for HCC?
If you already qualify for a liver transplant but are on a waiting list for an organ, doctors may use treatments like TACE, TARE, or thermal ablation to keep your tumor from growing. This is known as bridging therapy and helps ensure you remain eligible while you wait.
Is surgical resection or thermal ablation better for early HCC?
Surgical resection physically removes the tumor and is often the first choice if your liver is functioning well. Thermal ablation uses heat to destroy the tumor without major surgery and is highly effective for very small tumors under 3 centimeters. Your doctor will recommend the best option based on your liver's health and the tumor's size.
How does downstaging work for liver cancer?
Downstaging is a strategy used when your liver tumors are currently too large or numerous to qualify for a transplant. Doctors use therapies like TACE or ablation to shrink the tumors until they fall within the acceptable size limits for a transplant.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I meet the 'Milan criteria' for a transplant right now?
  2. 2.Given my liver function, would you recommend surgical resection or thermal ablation as my best first-line option?
  3. 3.If we use TACE or TARE, are we doing it to 'bridge' to a transplant or 'downstage' my tumors to help me qualify for one?
  4. 4.How will we monitor the effectiveness of my locoregional treatment to see if the tumor has been "killed" (necrosis)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    New frontiers in liver resection for hepatocellular carcinoma.

    Allaire M, Goumard C, Lim C, et al.

    JHEP reports : innovation in hepatology 2020; (2(4)):100134 doi:10.1016/j.jhepr.2020.100134.

    PMID: 32695968
  2. 2

    Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.

    Yen YH, Cheng YF, Wang JH, et al.

    PloS one 2021; (16(3)):e0249194 doi:10.1371/journal.pone.0249194.

    PMID: 33765059
  3. 3

    Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors.

    Ohkubo T, Midorikawa Y, Nakayama H, et al.

    Hepatology research : the official journal of the Japan Society of Hepatology 2018; (48(6)):433-441 doi:10.1111/hepr.13047.

    PMID: 29277961
  4. 4

    Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.

    Xia F, Zhang Q, Ndhlovu E, et al.

    Surgical endoscopy 2024; (38(2)):799-812 doi:10.1007/s00464-023-10589-7.

    PMID: 38062182
  5. 5

    Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.

    Alim A, Erdogan Y, Dayangac M, et al.

    Cancer control : journal of the Moffitt Cancer Center 2021; (28()):10732748211011960 doi:10.1177/10732748211011960.

    PMID: 33926242
  6. 6

    Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review.

    Alim A, Karataş C

    Journal of gastrointestinal cancer 2021; (52(4)):1223-1231 doi:10.1007/s12029-021-00730-x.

    PMID: 34882291
  7. 7

    Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6.

    Sun H, Tang H, Xie D, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(2)):502-12 doi:10.1158/1078-0432.CCR-15-0528.

    PMID: 26338995
  8. 8

    MWA Versus RFA in HCC: Superior? Equivalent? Will We Ever Know?

    Guiu B

    Cardiovascular and interventional radiology 2020; (43(11)):1619-1620 doi:10.1007/s00270-020-02635-x.

    PMID: 32909065
  9. 9

    Comparative Efficacy of Microwave versus Radiofrequency Ablation in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

    Rey I, Darmadi D

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2024; (62(4)):374-386 doi:10.2478/rjim-2024-0022.

    PMID: 38905615
  10. 10

    Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study.

    Hsiao CY, Hu RH, Ho CM, et al.

    American journal of surgery 2020; (220(4)):958-964 doi:10.1016/j.amjsurg.2020.03.017.

    PMID: 32247523
  11. 11

    Survival Outcome Was Better with Liver Resection than with Percutaneous Radiofrequency Ablation in Patients with Very Early-Stage Hepatocellular Carcinoma: A Single-Center Retrospective Study.

    Yen YH, Liu YW, Hung CH, et al.

    Journal of investigative surgery : the official journal of the Academy of Surgical Research 2026; (39(1)):2625532 doi:10.1080/08941939.2026.2625532.

    PMID: 41660702
  12. 12

    Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging.

    Chiu RY, Yap WW, Patel R, et al.

    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2016; (67(2)):158-72.

    PMID: 26961737
  13. 13

    Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.

    Manjunatha N, Ganduri V, Rajasekaran K, et al.

    Cureus 2022; (14(8)):e28439 doi:10.7759/cureus.28439.

    PMID: 36176866
  14. 14

    Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.

    Yang B, Liang J, Qu Z, et al.

    PloS one 2020; (15(2)):e0227475 doi:10.1371/journal.pone.0227475.

    PMID: 32074102
  15. 15

    Prevalence and Risk Factors of Post-chemoembolization Syndrome After Chemo-Embolization for Hepatocellular Carcinoma in Thailand.

    Thanakunchai T, Hongthanakorn C

    Digestive diseases and sciences 2023; (68(9)):3818-3823 doi:10.1007/s10620-023-08010-3.

    PMID: 37402085
  16. 16

    Bridging locoregional treatment prior to liver transplantation for cirrhotic patients with hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis.

    Kostakis ID, Dimitrokallis N, Iype S

    Annals of gastroenterology 2023; (36(4)):449-458 doi:10.20524/aog.2023.0812.

    PMID: 37396004
  17. 17

    Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.

    Wedd JP, Nordstrom E, Nydam T, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2015; (21(12)):1543-52 doi:10.1002/lt.24356.

    PMID: 26457885
  18. 18

    Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.

    Kim Y, Stahl CC, Makramalla A, et al.

    Surgery 2017; (162(6)):1250-1258 doi:10.1016/j.surg.2017.08.007.

    PMID: 29033224
  19. 19

    Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.

    Shi F, Wu M, Lian SS, et al.

    Radiology 2019; (293(3)):707-715 doi:10.1148/radiol.2019181991.

    PMID: 31638492
  20. 20

    Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma.

    Chong CC, Chan AW, Wong J, et al.

    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2018; (16(3)):163-170 doi:10.1016/j.surge.2017.07.003.

    PMID: 28807570
  21. 21

    Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.

    Wu X, Chen R, Zheng W, Hu H

    Technology in cancer research & treatment 2018; (17()):1533033818759878 doi:10.1177/1533033818759878.

    PMID: 29739274

This page provides educational information about early and intermediate HCC treatments. Always consult your oncology team, hepatologist, or transplant coordinator to determine the safest and most effective treatment plan for your specific liver function and tumor stage.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.